Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
| Autor: | Christian Brandl, Sandrine d’Argouges, Ralf C. Bargou, Sandra Wissing, Peter Kufer, Alex Kozhich, Mathias Locher, Nadja Prang, Ralf Lutterbuese, Robert Hofmeister, Patrick A. Baeuerle, JoAnn Suzich, Peter A. Kiener |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cytotoxicity
Immunologic Cancer Research Lymphoma B-Cell CD3 Complex T cell Antigens CD19 CD19 Granzymes Antibodies Monoclonal Murine-Derived Antigen immune system diseases hemic and lymphatic diseases Antibodies Bispecific Antineoplastic Combined Chemotherapy Protocols medicine Tumor Cells Cultured Cytotoxic T cell Humans Caspase 7 biology Chemistry Caspase 3 Antibodies Monoclonal Drug Synergism Hematology medicine.disease Lymphoma medicine.anatomical_structure Oncology Granzyme Immunology biology.protein Blinatumomab Rituximab medicine.drug |
| Zdroj: | Leukemia research. 33(3) |
| ISSN: | 1873-5835 |
| Popis: | We have compared the cytotoxic activity of rituximab with that of blinatumomab (MT103/MEDI-538), a single-chain CD19-/CD3-bispecific antibody engaging human T cells. Blinatumomab consistently led to a higher degree of lysis of human lymphoma lines than rituximab, and was active at much lower concentration. The cytotoxicity mediated by blinatumomab and rituximab both caused a potent activation of pro-caspases 3 and 7 in target cells, a key event in induction of granzyme-mediated apoptotic cell death. Combination of rituximab with blinatumomab was found to greatly enhance the activity of rituximab, in particular at low effector-to-target cell ratios and at low antibody concentration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect